Bionime Corp
TWSE:4737
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| TW |
|
Bionime Corp
TWSE:4737
|
3.9B TWD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
188.9B USD |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
172B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
138.8B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
131.1B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
114.7B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
59.5B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.2B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
51.7B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
46.7B USD |
Loading...
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
37.8B USD |
Loading...
|
Market Distribution
| Min | -22 082.4% |
| 30th Percentile | 1% |
| Median | 5.3% |
| 70th Percentile | 11.1% |
| Max | 1 580% |
Other Profitability Ratios
Bionime Corp
Glance View
Bionime Corp. engages in the manufacturing and selling of medical instruments, providing biotechnology services, examining pharmaceuticals, and selling precision instruments. The company is headquartered in Taichung, Taichung. The company went IPO on 2009-08-26. The firm's main products include blood glucose monitoring devices and blood glucose testing chips. Its products are applied in the testing and monitoring of blood glucose density. The firm distributes its products mainly to overseas markets, including Europe, Asia, the Americas and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Bionime Corp is -6.4%, which is below its 3-year median of -2.3%.
Over the last 3 years, Bionime Corp’s Net Margin has decreased from 4.5% to -6.4%. During this period, it reached a low of -7% on Mar 31, 2025 and a high of 4.5% on Aug 30, 2022.
